meropenem Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
analogues of penicillanic acid antibiotics modified in the five-membered ring 1709 96036-03-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • meropenem hydrate
  • meropenem
  • merrem
  • meropenem trihydrate
an antibacterial drug readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets, the bactericidal activity of meropenem results from the inhibition of cell wall synthesis
  • Molecular weight: 383.46
  • Formula: C17H25N3O5S
  • CLOGP: -3.28
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 110.18
  • ALOGS: -1.83
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g P
3 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 111.76 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.87 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 21, 1996 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 521.00 16.86 342 28495 55335 53264894
Septic shock 454.13 16.86 328 28509 61901 53258328
Drug resistance 309.95 16.86 170 28667 19792 53300437
Drug reaction with eosinophilia and systemic symptoms 305.36 16.86 201 28636 32599 53287630
Sepsis 289.02 16.86 375 28462 146054 53174175
Pathogen resistance 264.70 16.86 108 28729 6452 53313777
Febrile neutropenia 257.44 16.86 300 28537 104636 53215593
Pyrexia 204.00 16.86 576 28261 402617 52917612
Respiratory failure 195.86 16.86 256 28581 100256 53219973
Pain 171.31 16.86 53 28784 588345 52731884
Thrombocytopenia 168.60 16.86 283 28554 138444 53181785
Bronchopulmonary aspergillosis 166.17 16.86 85 28752 8580 53311649
Rheumatoid arthritis 151.50 16.86 4 28833 314527 53005702
Systemic candida 146.53 16.86 57 28780 3000 53317229
Toxic epidermal necrolysis 142.28 16.86 111 28726 23439 53296790
Haemophagocytic lymphohistiocytosis 142.28 16.86 78 28759 9059 53311170
Fatigue 138.13 16.86 116 28721 730390 52589839
Acute kidney injury 135.17 16.86 370 28467 253498 53066731
Pancytopenia 126.03 16.86 197 28640 90731 53229498
Headache 122.92 16.86 69 28768 536752 52783477
Arthralgia 118.47 16.86 45 28792 439738 52880491
Off label use 107.23 16.86 521 28316 471691 52848538
Clostridium difficile colitis 106.24 16.86 87 28750 19678 53300551
Enterococcal infection 105.06 16.86 60 28777 7538 53312691
Candida infection 103.01 16.86 95 28742 25178 53295051
Joint swelling 102.78 16.86 6 28831 234632 53085597
Fall 97.59 16.86 36 28801 358404 52961825
Acinetobacter infection 97.54 16.86 35 28802 1468 53318761
Neutropenia 96.80 16.86 244 28593 158941 53161288
Candida sepsis 90.65 16.86 33 28804 1443 53318786
Abdominal discomfort 90.08 16.86 8 28829 221054 53099175
Aspergillus infection 84.80 16.86 52 28785 7444 53312785
Acute respiratory distress syndrome 78.64 16.86 79 28758 23253 53296976
Fungaemia 78.21 16.86 33 28804 2144 53318085
Shock 77.35 16.86 78 28759 23061 53297168
Drug intolerance 77.18 16.86 10 28827 205483 53114746
Hepatic function abnormal 76.48 16.86 97 28740 36802 53283427
Pseudomonas infection 75.97 16.86 55 28782 10373 53309856
Dysbiosis 74.53 16.86 23 28814 599 53319630
Disseminated intravascular coagulation 74.36 16.86 71 28766 19648 53300581
Nasopharyngitis 73.08 16.86 9 28828 192286 53127943
Product dose omission issue 72.75 16.86 9 28828 191611 53128618
Klebsiella infection 72.30 16.86 48 28789 7878 53312351
Peripheral swelling 68.54 16.86 14 28823 206094 53114135
Agranulocytosis 68.53 16.86 74 28763 23675 53296554
Stenotrophomonas infection 68.03 16.86 28 28809 1708 53318521
Mucormycosis 66.32 16.86 31 28806 2569 53317660
Pneumonia 65.16 16.86 409 28428 406760 52913469
Eosinophilia 64.24 16.86 68 28769 21267 53298962
Acute generalised exanthematous pustulosis 63.25 16.86 49 28788 10232 53309997
Dizziness 63.09 16.86 65 28772 372194 52948035
Drug eruption 61.81 16.86 72 28765 25022 53295207
Myelosuppression 61.77 16.86 53 28784 12775 53307454
Swelling 61.46 16.86 14 28823 191091 53129138
Rash maculo-papular 59.74 16.86 77 28760 29672 53290557
Pain in extremity 59.02 16.86 41 28796 285009 53035220
Bacteraemia 58.65 16.86 56 28781 15493 53304736
Weight increased 58.26 16.86 19 28818 204548 53115681
Stevens-Johnson syndrome 58.00 16.86 69 28768 24513 53295716
Muscle spasms 57.34 16.86 4 28833 134791 53185438
Pseudomembranous colitis 56.55 16.86 30 28807 3261 53316968
Renal impairment 56.19 16.86 133 28704 83185 53237044
Depression 55.77 16.86 15 28822 183037 53137192
Cytokine release syndrome 54.98 16.86 41 28796 8088 53312141
Drug level decreased 54.59 16.86 38 28799 6736 53313493
Renal failure 53.51 16.86 163 28674 118289 53201940
Lactic acidosis 53.35 16.86 82 28755 37171 53283058
Asthenia 52.74 16.86 65 28772 343525 52976704
Contraindicated product administered 52.37 16.86 6 28831 135623 53184606
Pneumonia fungal 51.90 16.86 32 28805 4624 53315605
Geotrichum infection 50.48 16.86 16 28821 456 53319773
Neutropenic sepsis 50.09 16.86 50 28787 14599 53305630
Coagulopathy 49.32 16.86 57 28780 19641 53300588
Sinusitis 49.15 16.86 15 28822 168549 53151680
Linear IgA disease 48.57 16.86 21 28816 1449 53318780
Nocardiosis 48.56 16.86 23 28814 1964 53318265
Neutropenic colitis 48.44 16.86 25 28812 2568 53317661
Therapeutic product effect decreased 47.43 16.86 6 28831 125649 53194580
Acute respiratory failure 46.44 16.86 70 28767 31188 53289041
Platelet count decreased 46.27 16.86 146 28691 107953 53212276
Brain abscess 46.00 16.86 22 28815 1919 53318310
Gait disturbance 44.78 16.86 15 28822 158827 53161402
Malaise 44.75 16.86 78 28759 357539 52962690
Haemodynamic instability 44.44 16.86 37 28800 8557 53311672
Enterocolitis 44.23 16.86 34 28803 7018 53313211
Asthma 44.20 16.86 4 28833 108968 53211261
Hyperbilirubinaemia 43.91 16.86 41 28796 11028 53309201
Systemic inflammatory response syndrome 43.86 16.86 31 28806 5629 53314600
Peritonitis 43.33 16.86 56 28781 21631 53298598
Weight decreased 43.29 16.86 38 28799 234910 53085319
Acute hepatic failure 42.90 16.86 49 28788 16671 53303558
Pneumonia bacterial 42.76 16.86 35 28802 7905 53312324
Cardiac arrest 42.39 16.86 129 28708 93538 53226691
Drug ineffective for unapproved indication 42.18 16.86 54 28783 20666 53299563
Fungal infection 42.04 16.86 68 28769 32178 53288051
Meningitis candida 41.82 16.86 9 28828 50 53320179
Anuria 41.69 16.86 42 28795 12398 53307831
Procalcitonin increased 41.29 16.86 16 28821 833 53319396
Insomnia 41.28 16.86 25 28812 187047 53133182
Systemic lupus erythematosus 40.68 16.86 9 28828 125405 53194824
Oliguria 40.12 16.86 36 28801 9202 53311027
C-reactive protein increased 40.08 16.86 103 28734 67783 53252446
Enterococcal sepsis 39.88 16.86 18 28819 1376 53318853
Musculoskeletal stiffness 39.72 16.86 9 28828 123359 53196870
Alopecia 39.64 16.86 41 28796 234542 53085687
Graft versus host disease 39.63 16.86 32 28805 7090 53313139
Blood bilirubin increased 39.50 16.86 70 28767 35660 53284569
Staphylococcal infection 39.41 16.86 73 28764 38475 53281754
Hyperlactacidaemia 38.96 16.86 22 28815 2703 53317526
Anticonvulsant drug level decreased 38.64 16.86 17 28820 1223 53319006
Acute myeloid leukaemia 37.45 16.86 46 28791 16886 53303343
Anxiety 37.22 16.86 31 28806 196673 53123556
Weissella infection 37.05 16.86 7 28830 17 53320212
Excessive eye blinking 36.94 16.86 15 28822 884 53319345
Hyperchloraemia 36.00 16.86 14 28823 736 53319493
Perinephric abscess 35.58 16.86 10 28827 186 53320043
Eosinophilic pneumonia acute 35.56 16.86 12 28825 418 53319811
Multiple-drug resistance 35.46 16.86 22 28815 3213 53317016
Nausea 35.27 16.86 252 28585 755839 52564390
Factor V inhibition 35.24 16.86 10 28827 193 53320036
Fungal sepsis 35.01 16.86 16 28821 1259 53318970
Guillain-Barre syndrome 34.76 16.86 23 28814 3752 53316477
Drug interaction 34.75 16.86 220 28617 219109 53101120
Feeling abnormal 34.43 16.86 15 28822 135286 53184943
Blood lactate dehydrogenase increased 34.11 16.86 50 28787 21731 53298498
Mucosal inflammation 34.08 16.86 73 28764 42711 53277518
Hepatic infarction 34.05 16.86 13 28824 650 53319579
Leukopenia 34.00 16.86 102 28735 73361 53246868
Pleural effusion 33.73 16.86 115 28722 88464 53231765
Product use in unapproved indication 33.71 16.86 135 28702 112154 53208075
Bone marrow failure 33.29 16.86 59 28778 30056 53290173
Alanine aminotransferase increased 33.22 16.86 120 28717 94975 53225254
Wound 33.06 16.86 5 28832 91552 53228677
Metabolic acidosis 32.42 16.86 71 28766 42171 53278058
Umbilical erythema 32.11 16.86 8 28829 91 53320138
Transaminases increased 31.98 16.86 58 28779 30074 53290155
Trichosporon infection 31.89 16.86 10 28827 275 53319954
Toxic encephalopathy 31.65 16.86 26 28811 5901 53314328
Rhinocerebral mucormycosis 31.32 16.86 9 28828 182 53320047
Clostridium difficile infection 31.28 16.86 55 28782 27838 53292391
Neurotoxicity 31.24 16.86 40 28797 15309 53304920
Product deposit 30.91 16.86 9 28828 191 53320038
Injection site erythema 30.88 16.86 3 28834 77246 53242983
Encephalopathy 30.71 16.86 64 28773 36744 53283485
Nephropathy toxic 30.68 16.86 30 28807 8542 53311687
Blood pressure increased 30.67 16.86 19 28818 140460 53179769
Emphysematous pyelonephritis 30.47 16.86 9 28828 201 53320028
Renal abscess 29.88 16.86 12 28825 687 53319542
Scedosporium infection 29.50 16.86 11 28826 515 53319714
Pneumothorax 29.36 16.86 39 28798 15468 53304761
Pyelonephritis fungal 29.25 16.86 8 28829 134 53320095
Mixed liver injury 29.23 16.86 21 28816 3912 53316317
Anaemia 29.21 16.86 252 28585 276466 53043763
Haemorrhage intracranial 29.09 16.86 36 28801 13316 53306913
Haemostasis 28.93 16.86 9 28828 241 53319988
Arthritis 28.84 16.86 6 28831 87292 53232937
Brain oedema 28.65 16.86 36 28801 13522 53306707
Contusion 28.61 16.86 12 28825 110720 53209509
Abscess neck 28.58 16.86 11 28826 562 53319667
Hepatic failure 28.41 16.86 61 28776 35745 53284484
Central nervous system injury 28.41 16.86 8 28829 150 53320079
Adjusted calcium decreased 28.36 16.86 8 28829 151 53320078
Hypoxia 28.35 16.86 80 28757 55600 53264629
Posterior reversible encephalopathy syndrome 28.10 16.86 39 28798 16121 53304108
Drug hypersensitivity 27.86 16.86 64 28773 265178 53055051
Cholestasis 27.66 16.86 53 28784 28642 53291587
Cytopenia 27.20 16.86 29 28808 9141 53311088
Escherichia infection 27.07 16.86 33 28804 12017 53308212
Discomfort 26.92 16.86 9 28828 95463 53224766
Mycobacterium abscessus infection 26.83 16.86 11 28826 664 53319565
Hypotension 26.61 16.86 231 28606 253845 53066384
Seizure 26.43 16.86 139 28698 129370 53190859
Drug ineffective 26.22 16.86 601 28236 816644 52503585
Hypernatraemia 26.01 16.86 25 28812 6972 53313257
Aspartate aminotransferase increased 26.00 16.86 102 28735 83927 53236302
Blood alkaline phosphatase increased 25.70 16.86 64 28773 41298 53278931
Migraine 25.61 16.86 6 28831 80411 53239818
Disease progression 25.53 16.86 116 28721 101804 53218425
Hyperchlorhydria 25.48 16.86 14 28823 1632 53318597
Escherichia bacteraemia 25.36 16.86 18 28819 3290 53316939
Hyperoxaluria 25.33 16.86 7 28830 122 53320107
Gamma-glutamyltransferase increased 25.30 16.86 56 28781 33499 53286730
Myocardial infarction 25.29 16.86 11 28826 99343 53220886
Splenic injury 25.24 16.86 8 28829 228 53320001
Liver abscess 25.23 16.86 17 28820 2858 53317371
Globulins decreased 25.14 16.86 8 28829 231 53319998
Respiratory distress 24.99 16.86 56 28781 33771 53286458
Cross sensitivity reaction 24.94 16.86 15 28822 2072 53318157
Cytomegalovirus test positive 24.91 16.86 17 28820 2918 53317311
Noninfectious peritonitis 24.85 16.86 8 28829 240 53319989
Haemorrhagic disorder 24.75 16.86 11 28826 811 53319418
Diabetic macroangiopathy 24.67 16.86 7 28830 135 53320094
Hypoalbuminaemia 24.65 16.86 30 28807 10906 53309323
Tubulointerstitial nephritis 24.57 16.86 37 28800 16467 53303762
Death neonatal 24.54 16.86 8 28829 250 53319979
Pericarditis 24.48 16.86 3 28834 64403 53255826
Pseudomonal sepsis 24.35 16.86 15 28822 2164 53318065
Abdominal pain upper 23.88 16.86 33 28804 166258 53153971
Type IV hypersensitivity reaction 23.82 16.86 16 28821 2676 53317553
Cerebral mass effect 23.65 16.86 11 28826 901 53319328
Herpes simplex viraemia 23.34 16.86 7 28830 165 53320064
Toxic skin eruption 23.28 16.86 32 28805 13107 53307122
Acute graft versus host disease in skin 23.18 16.86 17 28820 3269 53316960
Hypochromasia 22.95 16.86 8 28829 308 53319921
Hyperhidrosis 22.68 16.86 12 28825 96781 53223448
Osteomyelitis bacterial 22.66 16.86 7 28830 183 53320046
Hypotonia 22.59 16.86 26 28811 8915 53311314
Venoocclusive disease 22.59 16.86 14 28823 2041 53318188
Klebsiella bacteraemia 22.57 16.86 12 28825 1310 53318919
Bacterial sepsis 22.47 16.86 18 28819 3944 53316285
Vulvovaginitis 22.47 16.86 8 28829 328 53319901
Colitis 22.43 16.86 61 28776 41491 53278738
Somnolence 22.41 16.86 35 28802 167699 53152530
Lung abscess 22.39 16.86 13 28824 1684 53318545
Infusion related reaction 22.34 16.86 31 28806 155926 53164303
Folate deficiency 22.29 16.86 14 28823 2090 53318139
Herpes simplex hepatitis 22.28 16.86 8 28829 336 53319893
Hypertransaminasaemia 22.25 16.86 18 28819 3998 53316231
Metabolic alkalosis 22.16 16.86 16 28821 3003 53317226
Dry mouth 22.09 16.86 3 28834 59547 53260682
Relapsing fever 21.97 16.86 7 28830 203 53320026
Diffuse large B-cell lymphoma refractory 21.92 16.86 11 28826 1065 53319164
Overgrowth fungal 21.91 16.86 6 28831 101 53320128
Morganella infection 21.47 16.86 9 28828 575 53319654
Intentional overdose 21.43 16.86 5 28832 67200 53253029
Hyperaemia 21.24 16.86 14 28823 2269 53317960
Hyperamylasaemia 21.20 16.86 8 28829 387 53319842
Endocarditis 21.15 16.86 20 28817 5464 53314765
Status epilepticus 21.14 16.86 33 28804 15151 53305078
Rash morbilliform 21.05 16.86 16 28821 3247 53316982
Candida endophthalmitis 21.03 16.86 5 28832 46 53320183
Anisocytosis 20.98 16.86 9 28828 609 53319620
Exfoliative rash 20.90 16.86 15 28822 2789 53317440
Cytomegalovirus viraemia 20.79 16.86 19 28818 4972 53315257
Neutrophil count decreased 20.69 16.86 66 28771 49032 53271197
Cerebrovascular accident 20.59 16.86 16 28821 105158 53215071
Hypersensitivity 20.40 16.86 53 28784 210612 53109617
Suicidal ideation 20.32 16.86 4 28833 60507 53259722
Hyperkalaemia 20.25 16.86 70 28767 54186 53266043
Venoocclusive liver disease 20.22 16.86 18 28819 4554 53315675
Acid base balance abnormal 20.22 16.86 7 28830 264 53319965
Hydrocephalus 20.01 16.86 19 28818 5217 53315012
Cytomegalovirus infection 19.96 16.86 37 28800 19502 53300727
Liver disorder 19.76 16.86 57 28780 40098 53280131
Cardiac failure congestive 19.61 16.86 13 28824 92744 53227485
Hepatitis fulminant 19.59 16.86 16 28821 3603 53316626
Delayed graft function 19.56 16.86 10 28827 1007 53319222
Bronchitis 19.51 16.86 19 28818 111880 53208349
Antibiotic level above therapeutic 19.47 16.86 7 28830 295 53319934
Serum sickness 19.43 16.86 14 28823 2619 53317610
Epilepsy 19.42 16.86 43 28794 25724 53294505
Acute graft versus host disease in intestine 19.40 16.86 12 28825 1744 53318485
Coagulation test abnormal 19.22 16.86 9 28828 749 53319480
Low cardiac output syndrome 19.16 16.86 7 28830 309 53319920
Blood fibrinogen decreased 19.15 16.86 9 28828 755 53319474
Abdominal sepsis 19.09 16.86 11 28826 1405 53318824
Chest pain 19.07 16.86 47 28790 190138 53130091
Pulmonary haemorrhage 18.95 16.86 21 28816 6912 53313317
Systemic mycosis 18.89 16.86 10 28827 1082 53319147
Septal panniculitis 18.73 16.86 5 28832 76 53320153
Herpes simplex 18.73 16.86 22 28815 7707 53312522
Pulmonary sepsis 18.53 16.86 11 28826 1484 53318745
Clostridium test positive 18.53 16.86 13 28824 2333 53317896
Thrombotic microangiopathy 18.48 16.86 24 28813 9313 53310916
Acute myeloid leukaemia recurrent 18.41 16.86 11 28826 1502 53318727
Hyperammonaemia 18.39 16.86 18 28819 5131 53315098
Encephalitis 18.24 16.86 22 28815 7922 53312307
Dermatitis exfoliative generalised 18.12 16.86 15 28822 3440 53316789
Vision blurred 18.10 16.86 12 28825 85592 53234637
Musculoskeletal pain 18.10 16.86 9 28828 75191 53245038
Influenza 18.06 16.86 15 28822 95364 53224865
Injection site reaction 18.00 16.86 3 28834 51163 53269066
Kussmaul respiration 17.98 16.86 6 28831 202 53320027
Inappropriate schedule of product administration 17.96 16.86 9 28828 74869 53245360
Liver injury 17.93 16.86 38 28799 22065 53298164
Hospitalisation 17.86 16.86 8 28829 71004 53249225
CNS ventriculitis 17.84 16.86 5 28832 92 53320137
Fusarium infection 17.73 16.86 8 28829 611 53319618
Pulseless electrical activity 17.70 16.86 21 28816 7433 53312796
Sepsis syndrome 17.59 16.86 9 28828 908 53319321
Serratia infection 17.49 16.86 9 28828 919 53319310
Abdominal compartment syndrome 17.49 16.86 8 28829 631 53319598
Cardiomyopathy acute 17.44 16.86 6 28831 222 53320007
Oedema peripheral 17.28 16.86 42 28795 170745 53149484
Leukocytosis 17.22 16.86 40 28797 24694 53295535
Clostridial sepsis 17.12 16.86 7 28830 420 53319809
Calcification of muscle 17.11 16.86 4 28833 34 53320195
Pneumonia cytomegaloviral 17.07 16.86 12 28825 2160 53318069
Rhinorrhoea 17.05 16.86 4 28833 53574 53266655
Nosocomial infection 17.05 16.86 11 28826 1720 53318509
Blast cell count increased 17.02 16.86 7 28830 426 53319803
Gastrooesophageal reflux disease 16.93 16.86 12 28825 82651 53237578
Wound haemorrhage 16.90 16.86 12 28825 2195 53318034
Clostridial infection 16.87 16.86 16 28821 4386 53315843

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 475.79 14.64 495 37984 69359 32405688
Septic shock 461.13 14.64 484 37995 68505 32406542
Drug resistance 341.52 14.64 254 38225 22711 32452336
Pathogen resistance 333.39 14.64 181 38298 9329 32465718
Drug reaction with eosinophilia and systemic symptoms 287.63 14.64 266 38213 32219 32442828
Bronchopulmonary aspergillosis 220.62 14.64 159 38320 13528 32461519
Sepsis 220.50 14.64 541 37938 158293 32316754
Drug ineffective 201.41 14.64 940 37539 382537 32092510
Fatigue 181.31 14.64 95 38384 350606 32124441
Enterococcal infection 179.65 14.64 120 38359 9027 32466020
Pyrexia 165.91 14.64 782 37697 319186 32155861
Off label use 164.93 14.64 757 37722 305563 32169484
Respiratory failure 164.62 14.64 380 38099 106802 32368245
Candida infection 163.16 14.64 145 38334 16658 32458389
Disseminated intravascular coagulation 153.38 14.64 162 38317 23014 32452033
Hepatic function abnormal 142.03 14.64 217 38262 44623 32430424
Eosinophilia 141.78 14.64 161 38318 24797 32450250
Dizziness 137.49 14.64 39 38440 209579 32265468
Haemophagocytic lymphohistiocytosis 137.10 14.64 111 38368 11224 32463823
Fall 127.74 14.64 37 38442 196164 32278883
Klebsiella infection 126.63 14.64 92 38387 7920 32467127
Febrile neutropenia 120.17 14.64 362 38117 119204 32355843
Rash maculo-papular 111.24 14.64 151 38328 27871 32447176
Systemic candida 104.45 14.64 57 38422 2964 32472083
Product dose omission issue 100.62 14.64 5 38474 102570 32372477
Toxic epidermal necrolysis 100.61 14.64 123 38356 20470 32454577
Pseudomonas infection 99.46 14.64 95 38384 11961 32463086
Death 96.91 14.64 192 38287 382325 32092722
Aspergillus infection 95.10 14.64 91 38388 11483 32463564
Pancytopenia 92.32 14.64 277 38202 90958 32384089
Myocardial infarction 90.86 14.64 19 38460 125657 32349390
Thrombocytopenia 87.28 14.64 377 38102 147922 32327125
Geotrichum infection 79.26 14.64 28 38451 497 32474550
Drug ineffective for unapproved indication 76.03 14.64 88 38391 13824 32461223
Drug abuse 75.35 14.64 5 38474 80238 32394809
Herpes simplex oesophagitis 73.89 14.64 20 38459 136 32474911
Pain 73.83 14.64 68 38411 187488 32287559
Headache 72.76 14.64 75 38404 196122 32278925
Bone marrow failure 71.80 14.64 129 38350 30275 32444772
Dysbiosis 71.33 14.64 25 38454 433 32474614
Depression 65.51 14.64 17 38462 97043 32378004
Acute respiratory distress syndrome 64.62 14.64 111 38368 25142 32449905
Asthenia 61.68 14.64 116 38363 235828 32239219
Mucormycosis 61.34 14.64 52 38427 5602 32469445
Anxiety 60.76 14.64 19 38460 95986 32379061
Arthralgia 60.58 14.64 52 38427 148396 32326651
Renal impairment 59.64 14.64 241 38238 91731 32383316
Stenotrophomonas infection 59.23 14.64 33 38446 1787 32473260
Fungaemia 58.92 14.64 37 38442 2502 32472545
Pseudomembranous colitis 57.19 14.64 39 38440 3033 32472014
Clostridium difficile infection 54.71 14.64 85 38394 17711 32457336
Trichosporon infection 54.68 14.64 24 38455 771 32474276
Hyphaema 54.47 14.64 21 38458 481 32474566
Drug-induced liver injury 54.15 14.64 100 38379 23963 32451084
Weight decreased 53.53 14.64 70 38409 164748 32310299
Pneumonia bacterial 52.31 14.64 64 38415 10652 32464395
Cholestasis 51.85 14.64 105 38374 26928 32448119
Back pain 51.58 14.64 34 38445 111019 32364028
Product use in unapproved indication 50.67 14.64 221 38258 86983 32388064
Clostridium difficile colitis 50.55 14.64 73 38406 14258 32460789
Pain in extremity 50.53 14.64 40 38439 118861 32356186
Inflammatory marker increased 50.41 14.64 39 38440 3690 32471357
Hepatomegaly 50.32 14.64 62 38417 10395 32464652
Brain abscess 49.35 14.64 35 38444 2899 32472148
Nausea 47.52 14.64 207 38272 320642 32154405
Agranulocytosis 47.20 14.64 93 38386 23384 32451663
Liver injury 47.19 14.64 70 38409 14004 32461043
Blood pressure increased 46.25 14.64 18 38461 79336 32395711
Feeling abnormal 46.04 14.64 8 38471 60415 32414632
Pulmonary haemorrhage 45.12 14.64 57 38422 9800 32465247
Liver abscess 44.66 14.64 36 38443 3615 32471432
Spinal muscular atrophy 43.94 14.64 16 38463 311 32474736
Systemic mycosis 43.89 14.64 25 38454 1413 32473634
Joint swelling 43.74 14.64 5 38474 51730 32423317
Cardiac failure congestive 43.60 14.64 23 38456 84829 32390218
Inappropriate schedule of product administration 42.58 14.64 3 38476 45822 32429225
Pneumonia 42.58 14.64 622 37857 354630 32120417
Gait disturbance 42.50 14.64 21 38458 80387 32394660
Myalgia 41.76 14.64 22 38457 81208 32393839
Fungal infection 41.60 14.64 69 38410 15186 32459861
Rheumatoid arthritis 41.15 14.64 3 38476 44541 32430506
Muscle spasms 40.99 14.64 16 38463 70402 32404645
Tachypnoea 40.62 14.64 72 38407 16711 32458336
Coagulopathy 39.89 14.64 78 38401 19499 32455548
Pneumococcal sepsis 39.87 14.64 20 38459 873 32474174
Nocardiosis 39.83 14.64 34 38445 3697 32471350
Pneumothorax 39.50 14.64 73 38406 17497 32457550
Coronary artery disease 39.17 14.64 6 38473 49700 32425347
Syncope 38.68 14.64 30 38449 90094 32384953
Drug eruption 38.61 14.64 76 38403 19090 32455957
Hypoalbuminaemia 38.49 14.64 58 38421 11764 32463283
Bacteraemia 38.07 14.64 72 38407 17561 32457486
Chest pain 37.99 14.64 55 38424 124082 32350965
Hypofibrinogenaemia 37.31 14.64 24 38455 1692 32473355
Aeromonas infection 37.14 14.64 14 38465 301 32474746
Enterococcus test positive 36.94 14.64 19 38460 875 32474172
C-reactive protein increased 36.86 14.64 133 38346 47969 32427078
Hepatic failure 36.65 14.64 109 38370 35571 32439476
Cough 36.42 14.64 68 38411 138749 32336298
Nasopharyngitis 36.30 14.64 15 38464 63772 32411275
Ototoxicity 36.17 14.64 23 38456 1589 32473458
Aplastic anaemia 35.93 14.64 44 38435 7329 32467718
Hyperhidrosis 35.52 14.64 20 38459 71148 32403899
Leukopenia 35.38 14.64 153 38326 59969 32415078
Neutropenia 35.23 14.64 288 38191 141887 32333160
Dyspnoea 34.58 14.64 269 38210 361776 32113271
Enterocolitis 34.48 14.64 43 38436 7297 32467750
Weight increased 34.47 14.64 29 38450 83634 32391413
Abdominal discomfort 34.02 14.64 10 38469 52614 32422433
Serum sickness-like reaction 33.11 14.64 10 38469 105 32474942
Dehydration 33.10 14.64 64 38415 128894 32346153
Acute generalised exanthematous pustulosis 33.10 14.64 40 38439 6573 32468474
Hepatotoxicity 32.30 14.64 71 38408 19266 32455781
Myelosuppression 32.09 14.64 53 38426 11623 32463424
Vomiting 31.83 14.64 157 38322 235400 32239647
Hypoxia 31.70 14.64 134 38345 51998 32423049
Platelet count decreased 31.61 14.64 238 38241 114353 32360694
Respiratory gas exchange disorder 31.35 14.64 14 38465 469 32474578
Cytomegalovirus infection 31.26 14.64 83 38396 25381 32449666
Cross sensitivity reaction 30.71 14.64 20 38459 1440 32473607
Rectal haemorrhage 30.69 14.64 4 38475 37419 32437628
Intentional overdose 30.63 14.64 6 38473 41595 32433452
Respiratory tract infection bacterial 30.48 14.64 15 38464 628 32474419
Hospitalisation 30.42 14.64 10 38469 48961 32426086
Portal fibrosis 30.36 14.64 13 38466 393 32474654
Cytokine release syndrome 30.13 14.64 56 38423 13479 32461568
Hyperferritinaemia 30.02 14.64 13 38466 404 32474643
Acinetobacter infection 29.99 14.64 18 38461 1122 32473925
Tubulointerstitial nephritis 29.50 14.64 69 38410 19508 32455539
Vision blurred 29.30 14.64 8 38471 44178 32430869
Encephalopathy 29.08 14.64 98 38381 34159 32440888
Shock 29.00 14.64 78 38401 24036 32451011
Clostridium test positive 28.66 14.64 23 38456 2294 32472753
Staphylococcal sepsis 28.60 14.64 46 38433 9867 32465180
Neutropenic colitis 28.50 14.64 24 38455 2561 32472486
Epidermolysis bullosa 28.41 14.64 9 38470 112 32474935
Rash morbilliform 28.35 14.64 25 38454 2839 32472208
Insomnia 28.26 14.64 47 38432 100301 32374746
Pneumonia fungal 28.24 14.64 36 38443 6244 32468803
Incorrect dose administered 28.12 14.64 4 38475 35024 32440023
Respiratory paralysis 28.10 14.64 8 38471 67 32474980
Acute myeloid leukaemia recurrent 27.88 14.64 21 38458 1909 32473138
Sputum increased 27.87 14.64 22 38457 2143 32472904
Wound dehiscence 27.79 14.64 27 38452 3469 32471578
Cerebrovascular accident 27.64 14.64 37 38442 86283 32388764
Liver disorder 27.27 14.64 91 38388 31563 32443484
Dermatitis bullous 27.03 14.64 36 38443 6517 32468530
Endocarditis 26.98 14.64 36 38443 6528 32468519
Venoocclusive liver disease 26.68 14.64 38 38441 7327 32467720
Eosinophilic pneumonia 26.61 14.64 25 38454 3081 32471966
Constipation 26.50 14.64 70 38409 126303 32348744
Balance disorder 26.44 14.64 7 38472 39452 32435595
Aggression 26.36 14.64 7 38472 39382 32435665
Musculoskeletal stiffness 26.24 14.64 7 38472 39257 32435790
Therapeutic product effect decreased 26.21 14.64 3 38476 31014 32444033
Multiple-drug resistance 26.05 14.64 27 38452 3748 32471299
Wrong technique in product usage process 25.93 14.64 5 38474 35054 32439993
Oedema peripheral 25.63 14.64 61 38418 114030 32361017
Nosocomial infection 25.56 14.64 17 38462 1268 32473779
Condition aggravated 25.50 14.64 289 38190 155372 32319675
Hypertension 25.39 14.64 76 38403 131674 32343373
Chronic obstructive pulmonary disease 25.35 14.64 13 38466 48740 32426307
Tumour lysis syndrome 24.96 14.64 54 38425 14493 32460554
Hepatic cytolysis 24.49 14.64 39 38440 8294 32466753
Pneumonia klebsiella 24.29 14.64 23 38456 2862 32472185
Contusion 24.28 14.64 5 38474 33463 32441584
Vascular pseudoaneurysm thrombosis 24.24 14.64 7 38472 62 32474985
Treatment failure 24.06 14.64 101 38378 39062 32435985
Blood glucose increased 24.06 14.64 25 38454 65216 32409831
Acute myeloid leukaemia 24.04 14.64 63 38416 19111 32455936
Cardiac valve vegetation 23.96 14.64 12 38467 522 32474525
Factor V inhibition 23.81 14.64 9 38470 195 32474852
Abscess bacterial 23.55 14.64 9 38470 201 32474846
Granulocyte count decreased 23.48 14.64 13 38466 695 32474352
Acute graft versus host disease in skin 23.22 14.64 29 38450 4928 32470119
Increased bronchial secretion 22.90 14.64 18 38461 1743 32473304
Neurotoxicity 22.58 14.64 53 38426 15017 32460030
Asthma 22.54 14.64 12 38467 44053 32430994
Interleukin-2 receptor increased 22.39 14.64 8 38471 147 32474900
Haemorrhagic pneumonia 22.34 14.64 8 38471 148 32474899
Blood alkaline phosphatase increased 22.24 14.64 86 38393 32046 32443001
Peripheral swelling 22.17 14.64 29 38450 68316 32406731
Renal failure 22.16 14.64 250 38229 134228 32340819
CNS ventriculitis 22.00 14.64 9 38470 242 32474805
Deep vein thrombosis 21.75 14.64 26 38453 63687 32411360
Gastrooesophageal reflux disease 21.73 14.64 7 38472 34731 32440316
Alanine aminotransferase increased 21.62 14.64 163 38316 78316 32396731
Transaminases increased 21.60 14.64 72 38407 24956 32450091
Meningitis bacterial 21.59 14.64 15 38464 1202 32473845
Leukocytosis 21.59 14.64 69 38410 23398 32451649
Suicidal ideation 21.59 14.64 9 38470 38074 32436973
Enterococcal sepsis 21.54 14.64 17 38462 1656 32473391
Drug level decreased 21.52 14.64 32 38447 6414 32468633
Candida sepsis 21.35 14.64 15 38464 1224 32473823
Intentional product misuse 21.29 14.64 8 38471 36043 32439004
Chest X-ray abnormal 21.28 14.64 25 38454 3988 32471059
Loss of consciousness 21.25 14.64 41 38438 82666 32392381
Drug intolerance 21.19 14.64 17 38462 50218 32424829
Shock haemorrhagic 21.18 14.64 42 38437 10603 32464444
Procalcitonin increased 21.18 14.64 17 38462 1696 32473351
Mobility decreased 21.12 14.64 4 38475 28405 32446642
Toxicity to various agents 21.06 14.64 124 38355 177917 32297130
Stevens-Johnson syndrome 20.98 14.64 59 38420 18650 32456397
Eosinophilic pneumonia acute 20.92 14.64 11 38468 530 32474517
Necrotising fasciitis 20.85 14.64 24 38455 3745 32471302
Dyspnoea exertional 20.84 14.64 10 38469 38951 32436096
Enterobacter infection 20.84 14.64 19 38460 2254 32472793
COVID-19 20.79 14.64 84 38395 31931 32443116
Scedosporium infection 20.63 14.64 13 38466 884 32474163
Transient ischaemic attack 20.58 14.64 3 38476 25791 32449256
Radiation fibrosis - lung 20.48 14.64 5 38474 21 32475026
Urinary tract infection fungal 20.34 14.64 10 38469 418 32474629
Immune effector cell-associated neurotoxicity syndrome 20.33 14.64 16 38463 1552 32473495
Nephrogenic diabetes insipidus 20.31 14.64 15 38464 1323 32473724
Angina pectoris 20.26 14.64 6 38473 31420 32443627
Dysarthria 20.23 14.64 7 38472 33194 32441853
Paraesthesia 20.18 14.64 24 38455 58920 32416127
Dyspepsia 20.09 14.64 7 38472 33048 32441999
Nephrolithiasis 20.02 14.64 4 38475 27350 32447697
Dermatitis exfoliative generalised 19.94 14.64 22 38457 3279 32471768
Candida test positive 19.92 14.64 10 38469 437 32474610
Hepatic necrosis 19.82 14.64 24 38455 3951 32471096
Septic embolus 19.66 14.64 14 38465 1167 32473880
Sleep disorder 19.40 14.64 4 38475 26748 32448299
Blood bilirubin increased 19.31 14.64 94 38385 38690 32436357
Graft versus host disease in gastrointestinal tract 19.19 14.64 22 38457 3419 32471628
Acute respiratory failure 19.16 14.64 76 38403 28652 32446395
Acute kidney injury 19.08 14.64 468 38011 293000 32182047
Hypokalaemia 19.06 14.64 121 38358 54973 32420074
Antinuclear antibody negative 19.01 14.64 5 38474 30 32475017
Intra-abdominal fluid collection 18.92 14.64 14 38465 1239 32473808
Strongyloidiasis 18.91 14.64 19 38460 2542 32472505
Acute hepatic failure 18.76 14.64 45 38434 12924 32462123
Device related infection 18.61 14.64 55 38424 17878 32457169
Chimerism 18.58 14.64 8 38471 245 32474802
Faeces pale 18.54 14.64 15 38464 1514 32473533
Lung consolidation 18.29 14.64 27 38452 5376 32469671
Type IV hypersensitivity reaction 18.19 14.64 14 38465 1314 32473733
Myasthenia gravis crisis 18.14 14.64 10 38469 530 32474517
Myocardial calcification 18.11 14.64 5 38474 37 32475010
Mediastinitis 18.02 14.64 11 38468 707 32474340
Decreased appetite 17.97 14.64 114 38365 160699 32314348
Tremor 17.81 14.64 44 38435 81233 32393814
Vascular pseudoaneurysm 17.81 14.64 17 38462 2137 32472910
Heart rate decreased 17.80 14.64 4 38475 25196 32449851
Epilepsy 17.67 14.64 62 38417 22047 32453000
Coagulation time prolonged 17.64 14.64 14 38465 1374 32473673
Flavobacterium infection 17.50 14.64 6 38473 97 32474950
Arthritis 17.38 14.64 5 38474 26687 32448360
Fungal sepsis 17.31 14.64 12 38467 958 32474089
Blood lactate dehydrogenase increased 17.30 14.64 61 38418 21744 32453303
Graft versus host disease 17.28 14.64 39 38440 10767 32464280
Staphylococcal infection 17.15 14.64 80 38399 32359 32442688
Malaise 17.13 14.64 131 38348 177007 32298040
Gamma-glutamyltransferase increased 17.08 14.64 77 38402 30705 32444342
Hypernatraemia 17.01 14.64 33 38446 8200 32466847
Overdose 16.93 14.64 50 38429 87027 32388020
Potentiating drug interaction 16.92 14.64 25 38454 4983 32470064
Injection site pain 16.91 14.64 9 38470 33049 32441998
ADAMTS13 activity decreased 16.85 14.64 6 38473 109 32474938
Metabolic disorder 16.74 14.64 22 38457 3931 32471116
Hypoaesthesia 16.73 14.64 27 38452 58326 32416721
Dry mouth 16.69 14.64 4 38475 24115 32450932
Drug level increased 16.65 14.64 57 38422 20023 32455024
Chest discomfort 16.61 14.64 21 38458 50209 32424838
Macule 16.41 14.64 12 38467 1043 32474004
Soft tissue necrosis 16.39 14.64 8 38471 329 32474718
Muscular weakness 16.31 14.64 35 38444 67894 32407153
Acute graft versus host disease 16.28 14.64 28 38451 6342 32468705
Hyperbilirubinaemia 16.19 14.64 52 38427 17678 32457369
Respiratory distress 15.84 14.64 83 38396 35163 32439884
Hepatitis cholestatic 15.82 14.64 32 38447 8193 32466854
Circulatory collapse 15.82 14.64 58 38421 21067 32453980
Intestinal pseudo-obstruction 15.76 14.64 13 38466 1348 32473699
Amnesia 15.74 14.64 5 38474 25031 32450016
Staphylococcus test positive 15.60 14.64 19 38460 3146 32471901
Splenomegaly 15.60 14.64 45 38434 14432 32460615
Cytomegalovirus test positive 15.60 14.64 21 38458 3841 32471206
Cholangitis 15.47 14.64 32 38447 8326 32466721
Infective aneurysm 15.46 14.64 9 38470 530 32474517
Haemodynamic instability 15.45 14.64 33 38446 8778 32466269
Blood culture positive 15.36 14.64 24 38455 5021 32470026
Acoustic neuroma 15.34 14.64 6 38473 143 32474904
Bladder irrigation 15.31 14.64 5 38474 69 32474978
Plasma cell myeloma 15.29 14.64 28 38451 57586 32417461
Cholangiolitis 15.21 14.64 4 38475 24 32475023
Listeriosis 15.18 14.64 11 38468 942 32474105
Escherichia infection 15.16 14.64 29 38450 7131 32467916
Ependymitis 15.15 14.64 3 38476 3 32475044
Cystitis haemorrhagic 15.12 14.64 24 38455 5090 32469957
Linear IgA disease 15.12 14.64 14 38465 1694 32473353
Medication error 15.09 14.64 4 38475 22531 32452516
Dermatitis exfoliative 15.02 14.64 30 38449 7614 32467433
Hypoproteinaemia 14.93 14.64 15 38464 2006 32473041
Catheter site pain 14.93 14.64 12 38467 1200 32473847
Red blood cell sedimentation rate decreased 14.81 14.64 5 38474 77 32474970
Drug withdrawal syndrome 14.72 14.64 3 38476 20228 32454819
Retinopathy hypertensive 14.71 14.64 7 38472 272 32474775
Purpura non-thrombocytopenic 14.69 14.64 5 38474 79 32474968
Alveolitis necrotising 14.68 14.64 4 38475 28 32475019

Pharmacologic Action:

SourceCodeDescription
ATC J01DH02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Carbapenems
ATC J01DH52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Carbapenems
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:33282 antibacterials
CHEBI has role CHEBI:88188 allergenic drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Streptococcal meningitis indication 4510004 DOID:11574
Infection due to Pseudomonas aeruginosa indication 11218009
Peritonitis indication 48661000
Pneumococcal meningitis indication 51169003
Abdominal abscess indication 75100008
Bacterial meningitis indication 95883001 DOID:9470
Infectious disease of abdomen indication 128070006
Meningococcal meningitis indication 192644005
Complicated appendicitis indication 418171008
Peptostreptococcus Complicated Appendicitis indication
Pseudomonas Aeruginosa Complicated Appendicitis indication
E. Coli Complicated Appendicitis indication
Streptococcal Peritonitis indication
Bacteroides Peritonitis indication
Streptococcus Complicated Appendicitis indication
Klebsiella Pneumoniae Peritonitis indication
Complicated Skin and Skin Structure Infection indication
E. Coli Peritonitis indication
Peptostreptococcus Peritonitis indication
H. Influenzae Meningitis indication
Klebsiella Complicated Appendicitis indication
Bacteroides Complicated Appendicitis indication
Pyrexia of unknown origin off-label use 7520000
Bacterial septicemia off-label use 10001005 DOID:0040085
Inhalational anthrax off-label use 11389007
Nocardiosis off-label use 29227009 DOID:2312
Bacterial pneumonia off-label use 53084003 DOID:874
Cholangitis off-label use 82403002 DOID:9446
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Infection by Campylobacter fetus off-label use 111835002
Sepsis of the newborn off-label use 206376005
Sepsis syndrome off-label use 238150007
Diverticulitis of gastrointestinal tract off-label use 271366000
Neonatal meningitis off-label use 276674008
Anthrax off-label use 409498004 DOID:7427
Nosocomial pneumonia off-label use 425464007
Melioidosis off-label use 428111003 DOID:5052
Pneumonia due to Gram negative bacteria off-label use 430395005
Clostridium Perfringens Empyema off-label use
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Diabetic Foot Infection off-label use
Complicated Urinary Tract Infections off-label use
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic
pKa2 8.04 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1GM/VIAL;1GM/VIAL VABOMERE REMPEX N209776 Aug. 29, 2017 RX POWDER INTRAVENOUS 10183034 Aug. 8, 2031 TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
1GM/VIAL;1GM/VIAL VABOMERE REMPEX N209776 Aug. 29, 2017 RX POWDER INTRAVENOUS 10561675 Aug. 8, 2031 TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
1GM/VIAL;1GM/VIAL VABOMERE REMPEX N209776 Aug. 29, 2017 RX POWDER INTRAVENOUS 11007206 Aug. 8, 2031 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
1GM/VIAL;1GM/VIAL VABOMERE REMPEX N209776 Aug. 29, 2017 RX POWDER INTRAVENOUS 9694025 Aug. 8, 2031 TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1GM/VIAL;1GM/VIAL VABOMERE REMPEX N209776 Aug. 29, 2017 RX POWDER INTRAVENOUS Aug. 29, 2022 NEW CHEMICAL ENTITY
1GM/VIAL;1GM/VIAL VABOMERE REMPEX N209776 Aug. 29, 2017 RX POWDER INTRAVENOUS Aug. 29, 2027 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D-alanyl-D-alanine carboxypeptidase DacB Enzyme INHIBITOR DRUGBANK CHEMBL
Penicillin-binding protein 4 Enzyme WOMBAT-PK
D-ala-D-ala-carboxypeptidase; D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase family protein; Penicillin-binding protein 5 Enzyme WOMBAT-PK
Penicillin-binding protein 1 Enzyme WOMBAT-PK
D-alanyl-D-alanine carboxypeptidase; D-alanyl-D-alanine carboxypeptidase penicillin-binding protein 6 Enzyme WOMBAT-PK
Streptokinase A Enzyme EC50 6.90 WOMBAT-PK
Beta-lactamase class B VIM-2 Unclassified Kd 4.92 CHEMBL
Beta-lactamase NDM-1 Enzyme Kd 4.96 CHEMBL
Penicillin-binding protein 2 Enzyme WOMBAT-PK
Beta-lactamase Enzyme Kd 6.07 CHEMBL

External reference:

IDSource
4021008 VUID
N0000148477 NUI
D02222 KEGG_DRUG
4021008 VANDF
C0066005 UMLSCUI
CHEBI:43968 CHEBI
MEM PDB_CHEM_ID
CHEMBL127 ChEMBL_ID
DB00760 DRUGBANK_ID
D000077731 MESH_DESCRIPTOR_UI
441130 PUBCHEM_CID
10829 IUPHAR_LIGAND_ID
119478-56-7 SECONDARY_CAS_RN
FV9J3JU8B1 UNII
29561 RXNORM
173661 MMSL
5055 MMSL
6047 MMSL
d04027 MMSL
005166 NDDF
387540000 SNOMEDCT_US
725669004 SNOMEDCT_US
96062004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MERREM IV HUMAN PRESCRIPTION DRUG LABEL 1 0069-0313 INJECTION 500 mg INTRAVENOUS NDA 30 sections
MERREM IV HUMAN PRESCRIPTION DRUG LABEL 1 0069-0314 INJECTION 1 g INTRAVENOUS NDA 30 sections
Meropenem and Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0264-3183 INJECTION, SOLUTION 500 mg INTRAVENOUS NDA 26 sections
Meropenem and Sodium Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0264-3185 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 26 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 0409-1390 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 27 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 0409-1391 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
MEROPENEM HUMAN PRESCRIPTION DRUG LABEL 1 0781-3000 INJECTION 500 mg INTRAVENOUS ANDA 30 sections
MEROPENEM HUMAN PRESCRIPTION DRUG LABEL 1 0781-3098 INJECTION 1 g INTRAVENOUS ANDA 30 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 44567-145 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 44567-146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 44567-400 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 44567-401 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
MEROPENEM HUMAN PRESCRIPTION DRUG LABEL 1 44647-032 INJECTION 500 mg INTRAVENOUS ANDA 30 sections
MEROPENEM HUMAN PRESCRIPTION DRUG LABEL 1 44647-033 INJECTION 1 g INTRAVENOUS ANDA 30 sections
Meropenem Human Prescription Drug Label 1 55150-207 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 26 sections
Meropenem Human Prescription Drug Label 1 55150-208 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-507 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-507 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-507 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-508 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-508 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 63323-508 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 68001-323 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 27 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 68001-324 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
MEROPENEM HUMAN PRESCRIPTION DRUG LABEL 1 68001-446 INJECTION 500 mg INTRAVENOUS ANDA 29 sections
MEROPENEM HUMAN PRESCRIPTION DRUG LABEL 1 68001-447 INJECTION 1 g INTRAVENOUS ANDA 29 sections
Meropenem Human Prescription Drug Label 1 68083-146 INJECTION 500 mg INTRAVENOUS ANDA 27 sections
Meropenem Human Prescription Drug Label 1 68083-147 INJECTION 1 g INTRAVENOUS ANDA 27 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 70121-1453 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Meropenem HUMAN PRESCRIPTION DRUG LABEL 1 70121-1454 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 26 sections